Research Profile
Dr. Bertagnolli heads a research laboratory that focuses on the study of intestinal tumor biology as it relates to cancer prevention. The laboratory’s goal is to identify markers of early cancer development or cancer progression that can then be modulated to prevent tumors or to treat existing cancers more effectively. A major project of Dr. Bertagnolli’s laboratory is the investigation of the APC (Adenomatous Polyposis Coli) gene, an important factor in colorectal carcinogenesis. The laboratory also studies the relationship between the genetic composition of colon cancer and the response of the cancer to treatment.
Dr. Bertagnolli maintains an active role as a collaborator with the Strang Cancer Prevention Center and the Cancer and Leukemia Group B. As the Vice-Chair of the CALGB Gastrointestinal Committee, Dr. Bertagnolli reviews and facilitates the integration of molecular markers of treatment outcome into nation-wide clinical cancer treatment protocols. She is the Study Chair of several CALGB correlative science protocols designed to correlate tissue-specific changes with the clinical behavior of various gastrointestinal malignancies. Dr. Bertagnolli is also the Principal Investigator of an NCI-sponsored multi-institutional trial of selective cox-2 inhibition for prevention of colorectal adenomas.
Projects
DF/HCC SPORE in Gastrointestinal Cancer - Core 1
The main goal of the DF/HCC SPORE in GI Cancer is the translation of biological and technological advances into improvements in prevention, diagnostics, predictors of outcome, and advances in the treatment of gastrointestinal malignancies. There are five major projects 1) Improved pre-operative staging of pancreatic cancer; 2) Molecular fluorescent imaging for the early detection of colorectal neoplasms; 3)Defining optimal doses of vitamin D for chemoprevention in Blacks; 4) The role of P13-Kinase signaling pathway in defining sensitivity and resistance to anti-EGFR therapy in colorectal cancer; and 5) Targeted therapy resistance mechanisms in gastrointestinal stromal tumor.
Investigation of the APC (Adenomatous Polyposis Coli) gene
The laboratory is presently studying modulation of APC gene activity by chemopreventive drugs. This project emphasizes a translational research approach, as it includes examination of colorectal cancer cell lines, animals with APC gene mutation, and patients with Familial Adenomatous Polyposis, a human disease caused by mutation of the APC gene. This work is funded by the National Cancer Institute and by the Cancer Research Foundation of
Genetic composition of colon cancer and the response of the cancer to treatment
This work involves patients enrolled in the Strang-Cornell Hereditary Colon Cancer Database, and patients with colorectal cancer treated under Cancer and Leukemia Group B (CALGB) protocols. This project is funded through Cancer and Leukemia Group B, Strang Cancer Prevention Center, and American Cancer Society grants.
Selective cox-2 inhibition for prevention of colorectal adenomas
This 5-year, placebo-controlled, randomized study of 2,000 adenoma patients involves 14 major academic clinical centers. The study is designed to test whether the study drug prevents colorectal adenomas, but it will also characterize genetic and biochemical events in the intestinal tissues of participants, seeking correlates of chemoprevention efficacy. This trial, therefore, represents an integration of Dr. Bertagnolli’s basic research efforts with her clinical practice.
Bench research listing
- Epithelial Homeostatsis in APC Gene Mutation (Role: PI)
- Modulation of Tumor Formation in APC-Deficient Animals (Role: PI)
- Molecular Markers of Prognosis in Gastrointestinal Cancer (Role: PI)
Clinical research listing
- CALGB 9865: Relationship Between Tumor Replication Error (RER) Status and Treatment Outcome in a Colon Cancer Adjuvant Chemotherapy Trial (Role: PI & Study Chair)
- NCI-N01-CN-95015: Phase III Clinical Trial of Celecoxib for the Prevention of Sporadic Colorectal Adenomas (Role: PI)
- CALGB 150008: Familial Factors in the Development of Colon Cancer (Role: PI -- CALGB)
- CALGB 150105: STI-571 Response Predictors in Gastrointestinal Stromal Tumors (Role: Co-PI)
- CALGB 80001: Feasibility Study of Sentinel Lymph Node Staging For Colon Cancer (Role: PI and Study Chair)
- CALGB 80405: Predictors of Toxicity and Outcome in Patients Receiving Chemotherapy for Metastatic Colorectal Cancer (Role: CALGB Correlative Science Study Chair)
- ECOG E5202: A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers (Role: CALGB Study Chair)
Funding
Back to the top
Publications
| Original Articles | Review, Chapters, and Editorials | Clinical Communications |
For the latest articles by Dr. Monica Bertagnolli, please visit 
.
I. Origianl Articles
1. Bertagnolli M, Lawrence P, Stringfellow R. The Influence of Aorta-Aneurysm Geometry on Stress in the Aneurysm Wall. Journal of Surgical Research 1987;42(4):425-433.
2. Bertagnolli MM, Wilson RE, Burakoff SJ, Herrmann SH. Effect of Timing of Lymphokine Presentation on Generation of Cytotoxic T Lymphocytes. Archives of Surgery 1989;124:81-84.
3. Bertagnolli MM, Wilson RE, Herrmann SH. Production of Interleukin-6 In Vitro Parallels Development of Cytotoxic T Lymphocytes From Murine Thymocytes. Surgery 1989;106(2):332-338.
4. Bertagnolli MM, Herrmann SH. IL-7 Supports the Generation of Cytotoxic T Lymphocytes From Murine Thymocytes. Journal of Immunology 1990; 145(6):1706-1712
5. Bertagnolli MM, Takai Y, Herrmann SH. IL-4-Supported Induction of Cytotoxic T Lymphocytes Requires IL-2 and IL-6. Cellular Immunology 1991; 133(2):327-341.
6. Bertagnolli MM, Herrmann SH, Pinto VM, Schoof DD, Eberlein TJ. Approaches to Immunotherapy of Cancer: Characterization of Lymphokines as Second Signals for Cytotoxic T Cell Generation. Surgery 1991;110:459-468.
7. Bertagnolli MM, Lin B-Y, Young D, Herrmann SH. IL-12 Augments Antigen-Dependent Proliferation of Activated T Lymphocytes. Journal of Immunology 1992;149:3778-3783.
8. Andrews JVR, Schoof DD, Bertagnolli MM, Peoples GE, Goedegebuure P, Eberlein TJ. Immunomodulatory Effects of Interleukin-12 on Human Tumor-Infiltrating Lymphocytes. Journal of Immunotherapy 1993;14:1-10.
9. Bertagnolli MM, Yang L, Herrmann SH, Kirkman RL. Evidence that Rapamycin Inhibits IL-12-Induced Proliferation of Activated T Lymphocytes. Transplantation 1994;58(10):1091-1096.
10. Boolbol SK, Dannenberg AJ, Chadburn A, Martucci C, Guo X-J, Ramonetti JT, Abreu-Goris M, Newmark HL, Lipkin ML, DeCosse JJ, Bertagnolli MM. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Research1996;56(11):2556-2560.
11. Shyjan AM, Bertagnolli M, Kenney CJ, Briskin MJ. Human mucosal addressin cell adhesion molecule-1 (MAdCAM-1) demonstrates structural and functional similarities to the a4b7-integrin binding domains of murine MAdCAM-1, but extreme divergence of mucin-like sequences. Journal of Immunology 1996;156:2851-2857.
12. Mahmoud NN, Boolbol SK, Bilinski RT, Martucci CM, Chadburn A, Bertagnolli MM. Apc gene mutation is associated with a dominant negative effect upon intestinal cell migration. Cancer Research 1997;57(22); 5045-5050.
13. Mahmoud NN, Boolbol SK, Dannenberg AJ, Mestre JR, Bilinski RT, Newmark HL, Chadburn A, Bertagnolli MM. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis 1998;19:87-91.
14. Mahmoud NN, Dannenberg AJ, Mestre J, Bilinski RT, Churchill MR, Martucci C, Newmark H, Bertagnolli, MM. Aspirin prevents tumors in a murine model of familial adenomatous polyposis. Surgery 1998;124(2):225-231.
15. Mahmoud NN, Dannenberg AJ, Bilinski RT, Churchill MR, Mestre J, Martucci C, Bertagnolli MM. Administration of an Unconjugated Bile Acid Increases Duodenal Tumors in a Murine Model of Familial Adenomatous Polyposis. Carcinogenesis 1999;20:299-303.
16. Mahmoud NN, Kucherlapati R, Bilinski RT, Churchill MR, Chadburn A, Bertagnolli MM. Genotype-phenotype correlation in murine Apc mutation: Differences in enterocyte migration and response to sulindac. Cancer Research 1999;59:353-359.
17. Mahmoud NN, Carothers AM, Grunberger D, Bilinski RT, Churchill MR, Bertagnolli MM. Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis. Carcinogenesis 2000;21:921-927.
18. Weyant MJ, Carothers AC, Bertagnolli ME, Bertagnolli MM. Colon Cancer Chemopreventive Drugs Modulate Focal Adhesion Mediated Signaling Pathways. Clinical Cancer Research, 2000;6:949-956.
19. Churchill M, Chadburn A, Bilinski RT, Bertagnolli, MM. Inhibition of intestinal tumors by curcumin is associated with changes in the intestinal immune cell profile. J Surgical Research, 2000;89:169-175.
20. Weyant MJ, Carothers AM, Dannenberg AJ, Bertagnolli MM. (+)-Catechin inhibits intestinal tumor formation and suppresses focal adhesion kinase (FAK) activation in the Min/+ mouse. Cancer Research, 2001; 61:118-125.
21. Weyant MJ, Carothers AM, Mahmoud NN, Bradlow HL, Remotti H, Bilinski RT, Bertagnolli MM. Reciprocal expression of ERa and ERb is associated with estrogen-mediated modulation of intestinal carcinogenesis. Cancer Research, 2001; 61: 2547-2551.
22. Carothers AM, Melstrom KA Jr, Mueller JD, Weyant MJ, Bertagnolli MM. Progressive changes in adherens junction structure during intestinal adenoma formation in Apc-mutant mice. J Biol Chem, 2001; 276(42): 39094-39102.
23. O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS. Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gadzar AF, Wattenberg LW, Sporn MB, Skar WA, Lippman SM, Von Hoff DD. Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development: Recommendations of the American Association for Cancer Research Task Force on the Treatment and Prevention of Intraepithelial Neoplasia. Clin Cancer Res 2002; 8:314-346.
24. Carothers AM, Hughes SA, Bertagnolli MM. 2-Methoxyestradiol Induces p53-associated Apoptosis of Colorectal Cancer Cells. Cancer Letters 2002; 187(1-2):77-86.
25. Hughes SA, Carothers, AM, Hunt DH, Moran AE, Mueller JD, Bertagnolli MM. APC truncation alters cytoskeletal structure and microtubule stability in early intestinal tumorigenesis. J Gastrointest Surg, 2002; 6(6):868-875.
26. Cole DJ, Bertagnolli MM, Nussbaum M. Society of University Surgeons statement on surgical resident work hours and education. Surgery 2002; 132(2):115-118.
27. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Characterization of Sporadic Colon Cancer by Patterns of Genomic Instability. Cancer Research, 2003; 63(7): 1608-1614.
28. Goel A, Arnold CN, Niedzwiecki D, Carethers JM, Dowell, JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high (MSI-H) sporadic colorectal cancers. Cancer Research, 2004; 64(9):3014-3021.
29. Kulke MH, Odze RD, Mueller JD, Wang HH, Bertagnolli MM. Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer. J Thorac Cardiovasc Surg. 2004 Jun;127(6):1579-86.
30. Arnold CN, Goel A, Compton C, Marcus V, Niedzwiecki D, Dowell JM, Wasserman L, Inoue T, Mayer RJ, Bertagnolli MM, and Boland CR. Evaluation of Microsatellite Instability, hMLH1 expression and hMLH1 promoter hypermethylation in defining the MSI phenotype of colorectal cancer. Cancer Biology and Therapy, 2004; 3(1): 73-78.
31. Goel A, Arnold CN, Tassone P, Chang DK, Niedzwiecki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, and Boland CR. Epigenetic inactivation of RUNX3 in microsatellite unstable sporadic colon cancers. Int. J. Cancer, 2004; 112(5):754-759.
32. Moran AE, Hunt DH, Javid SH, Redston M, Carothers AM, Bertagnolli MM. Apc deficiency is associated with increased Egfr activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem, 2004; 279(4):43261-43272.
33. Bertagnolli MM, Miedema B, Redston M, Dowell J, Niedzwiecki D, Fleshman J, Bim J, Mayer R, Zinner M, Compton C: for the Cancer and Leukemia Group B. Sentinel Node Staging of Resectable Colon Cancer: Results of CALGB 80001 A Multicenter Study. Ann Surg 2004; 240(4):624-628.
34. Arnold CN, Goel A, Niedzweicki D, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. APC Promoter Hypermethylation Contributes to the Loss of APC Expression in Colorectal Cancers with Allelic Loss on 5q. Cancer Biology and Therapy 2004; 3(10): 960-964.
35. Javid SH, Moran AE, Carothers AM, Redston M, Bertagnolli MM. Modulation of tumor formation and intestinal cell migration by estrogens in the C57BL/6J-Min/+ (Min/+) mouse. Carcinogenesis 2005; 26(3): 587-595.
36. Moran AE, Carothers AM, Weyant MJ, Redston M, Bertagnolli MM. Carnosol inhibits b-catenin tyrosine phosphorylation and prevents adenoma formation in the C57BL/6J-Min/+ (Min/+) mouse. Cancer Research, 2005; 65(3):1097-1104.
37. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M. Cardiovascular risk associated with celecoxib in a clinical trial for adenoma prevention. New Engl J Med, 2005; 352 (11):1071-1080.
38. Carothers AM, Javid SH, Moran AE, Hunt DH, Redston M, Bertagnolli MM. Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Exp Cell Res. 2006; 312(4):387-400.
39. Redston M, Compton CC, Miedema BW, Niedzwiecki D, Dowell JM, Jewell SD, Fleshman JM, Bem J, Mayer RJ, Bertagnolli MM. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol. 2006 Feb 20;24(6):878-83. Epub 2006 Jan 17.
40. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20;24(15):2325-31.
41. Carothers AM, Moran AE, Cho NL, Redston M, Bertagnolli MM. Changes in antitumor response in C57BL/6J-Min/+ mice during long-term administration of a selective cyclooxygenase-2 inhibitor. Cancer Res. 2006 Jun 15;66(12):6432-8.
42. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET; APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006 Aug 31;355(9):873-84.
43. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, Eagle C, Hawk E, Lechuga M, Zauber AG, Bertagnolli MM, Arber N, Wittes J; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006 Sep 5;114(10):1028-35.
44. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG Island Methylator Phenotype and Chromosomal Instability Are Inversely Correlated in Sporadic Colorectal Cancer. Gastroenterology. 2006 Sep 20.
45. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007 Jan;132(1):127-38. Epub 2006 Sep 20.
46. Cho NL, Javid SH, Carothers AM, Redston M, Bertagnolli MM. Estrogen receptors alpha and beta are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Res. 2007 Mar 1;67(5):2366-72.
47. Bertagnolli MM. Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol. 2007 May;8(5):439-43.
48. Ito H, Hornick JL, Bertagnolli MM, George S, Morgan JA, Baldini EH, Wagner AJ, Demetri GD, Raut CP. Leiomyosarcoma of the inferior vena cava: survival after aggressive management. Ann Surg Oncol. 2007 Dec;14(12):3534-41. Epub 2007 Sep 25.
Back to the top
II. Reviews, Chapters, and Editorials
1. Osteen RT, Bertagnolli MM. Lymph Nodes and Subcutaneous Masses in The Office Practice of Medicine, William T. Branch, Jr. Ed., Philadelphia: Sanders, Third Edition, 1993.
2. Bertagnolli MM, DeCosse JJ. Guest Editorial: Laparoscopic Colectomy for Cancer. J Surg Oncol 1995; 58:211.
3. Bertagnolli MM, DeCosse JJ. Laparoscopic Colon Resection for Cancer (Against). Advances in Surgery 1996;29:155-160.
4. Bertagnolli MM, Mahmoud NN, Daly JM. Surgical aspects of colorectal carcinoma. Hematol Oncol Clin North Am. 1997 Aug;11(4):655-77. Review.
5. Bertagnolli MM, McDougall CM, Newmark HL. Colon Cancer Prevention: Intervening in a Multistage Process. Proc Soc Exp Bio Med, 1997;16(2); 266-274.
6. Newmark HL, Bertagnolli MM. Aspirin and Colon Cancer Prevention. Gastroenterology 1998;115:1036.
7. Daly JM, Bertagnolli MM, DeCosse JJ, Morton DM. Oncology. In: Principles of Surgery, Schwartz, Shires, Spencer, and Storer, Eds., 7th Edition, McGraw-Hill Co., New York, NY, 1998.
8. Bertagnolli MM. Cyclooxygenase-2 as a target for prevention of colorectal cancer. Current Oncology Reports 1999;1(2):173-178.
9. Augenlicht L, Bertagnolli MM. Apoptosis measurements in colon cancer chemoprevention studies. Cancer Research 1999;59(22):5856-5857.
10. Bertagnolli MM. Apc and Intestinal Tumorigenesis: Insights from animal models. Annals of the New York Academy of Science 1999; 889; 32-44.
11. Carothers AM, Bertagnolli MM, Weinstein IB. Mechanisms of Multistage Carcinogenesis in Surgical Oncology. In: Contemporary Principles & Practice, KI Bland, JM Daly, CP Karakousis, Eds., Appleton & Lange of Simon & Schuster, Stamford, CT, 2000.
12. Bertagnolli MM. Invited Commentary on: Tortola, et. al. P53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. (J Clin Oncol 1999; 17:1375-1381); In: Evidence-Based Oncology, 2000.
13. Bertagnolli MM. Gastrointestinal Cancer Management: Surgical Oncology. In: Gastrointestinal Oncology: Principles and Practice, DP Kelsen, JM Daly, S Kern, B Levin, and J Tepper, Eds., Lippincott Williams & Wilkins, Philadelphia, PA, 2001.
14. Bertagnolli, MM. Chemoprevention of Colorectal Cancer. In: Colorectal Cancer: Multimodality Management, LB Saltz, MD, Editor, Humana Press, Totowa, NJ, 2001.
15. Bertagnolli, MM. Colorectal Cancer Chemoprevention In: Strategies for Chemoprevention: Cancer Drug Discovery and Development Series, Humana Press, Totowa, NJ, 2002.
16. Bertagnolli MM. Bowel Obstruction. In: Clinical Practice of Hematology and Oncology: Presentations, Diagnosis and Treatment., B. Furie, RJ Mayer, PA Cassileth, MB Atkins, Eds., WB Saunders Co., Philadelphia, PA, 2003.
17. Bertagnolli MM. The Potential of Nonsteroidal Antiinflammatory Drugs (NSAIDs) for Colorectal Cancer Prevention, Journal of Surgical Oncology, 2003; 84(3): 113-119.
18. Bertagnolli MM. Principles of Gastrointestinal Surgical Oncology. B. Furie, RJ Mayer, PA Cassileth, MB Atkins, Eds., WB Saunders Co., Philadelphia, PA, 2003.
19. Bertagnolli MM. Colorectal Cancer Prevention Studies: The importance of defining risk. Annals of Surgical Oncology, 2003, 10(8): 829-830.
20. Bertagnolli MM, Hamilton SR. Chemoprevention of Colorectal Cancer: Clinical Strategies. In: Cancer Chemoprevention: Volume 2: Strategies for Cancer Chemoprevention. Eds GJ Kelloff, ET Hawk, CC Sigman. Humana Press, Totowa, NJ, 2004.
21. Bertagnolli MM. Eicosanoids. In: Encyclopedia of the Microvasculature, D. Shepro, Ed., 2005, in press.
22. Bertagnolli MM. Surgical Prevention of Cancer. Journal of Clinical Oncology, 2005, 23(2): 324-332.
23. Bertagnolli MM, Ashley S. Gastrointestinal Stromal Tumors. In: Maingot’s Abdominal Operations, 11th Edition, 2005.
24. Bertagnolli MM. Radioimmunotherapy for Colorectal Cancer. Clin Cancer Res. 2005 Jul 1;11(13):4637-8.
25. Bertagnolli MM. Cox-2 and cancer chemoprevention: picking up the pieces. Recent Results Cancer Res. 2007;174:73-8. Review.
Back to the top
III. Clinical Communications
1. Smith BL, Bertagnolli M, Klein BB, Batter S, Chang M, Douville LM, Eberlein TJ. Evaluation of the contralateral breast. The role of biopsy at the time of treatment of primary breast cancer. Ann Surg. 1992 Jul;216(1):17-21.
2. Axford TC, Clair DG, Bertagnolli MM, Mentzer SJ, Sugarbaker DJ. Staged Antrectomy and Thoracoscopic Truncal Vagotomy for Perforated Peptic Ulcer Disease. Annals of Thoracic Surgery, 55:1571-1573; 1993.
Report of a novel approach to vagotomy in a patient for whom a transabdominal approach was technically much more difficult.
3. Weyant MJ, Maluccio MA, Bertagnolli MM, Daly JM. Choledochal Cysts in Adults: A Report of Two Cases and Review of the Literature. Am J Gastroenterology, 93:2580-2583, 1998. General review of the management of choledochal cysts with a description of two illustrative cases.
4. Mahmoud NN, Mack CA, DeCosse JJ, Michaeli J, Bertagnolli MM. Debulking of a Gastrointestinal Hemangioma Alleviates Coagulopathy Associated with Kasabach-Merritt Syndrome. Surgery 125:236-238, 1999. The first report of successful management of severe bleeding disorder by debulking surgery, important in this case because it allowed anal sphincter preservation in a young man.
5. Weisberg MK, Bertagnolli MM, Becker DS. Combined sentinel lymphadenectomy and MOHS micrographic surgery for high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol 2000; 43:483-488. Description of application of sentinel lymph node biopsy to management of high risk head and neck squamous cell carcinoma.
6. George S, Hornick JL, Bertagnolli MM, Fletcher CDM, Demetri GD. Current management of metastatic gastrointestinal stromal tumor: A case report. Clinical Advances in Hematology & Oncology, 1(1); 63-65; 2003. Description of the role of surgery and imatinib mesylate in the management of patients with metastatic gastrointestinal stromal tumors.
Back to the top
Past and Present Research Fellows
-
Susan Boolbol, M.D. Laboratory research fellow 1995-1996.
The New York Presbyterian Hospital-Cornell; surgical oncology fellow, Memorial Sloan Kettering Cancer Center Breast Service, July, 2000; presently an Assistant Professor of Surgery, Albert Einstein College of Medicine, Attending, Beth Israel Medical Center, NY, NY.
-
Thomas Clancy, M.D. 2003-2005 Fineberg Fellow in Surgical Oncology.
Dana Farber – BWH Cancer Center. Dr. Bertagnolli served as Fellowship Director and Advisor; currently an Instructor in Surgery and Attending Surgeon, Harvard Medical School, Brigham and Women’s Hospital.
-
Sara Javid, M.D. Laboratory research fellow 2001-2003.
“Hormonal modulation of colorectal carcinogenesis”; awarded Ethicon-Society of University Surgeons Research Fellowship Award 2002-2003, awarded Cancer Research Foundation of America Research Fellowship 2001-2003.
-
Matthew Kulke, M.D. Mentor/sponsor for NCI K08 application.
“Markers of Outcome and Treatment Response in Esophageal Cancer”, 2001-present; currently a member of the Division of Medical Oncology, DFCI
-
Najjia Mahmoud, M.D. Laboratory research fellow 1996-1998.
The New York Presbyterian Hospital-Cornell; awarded independent research grants by the Society of Colon and Rectal Surgeons and the Cancer Research Foundation of America during her laboratory time; awarded American Association for Cancer Research outstanding Research Award for work in the laboratory; oral presentations at the SUS, SSO, AACR x2; completed a Colon and Rectal Surgery fellowship at the University of Minnesota, July, 2000, presently an Assistant Professor of Surgery, University of Pennsylvania.
-
Sara Russell, M.D. 2002-2004 Fineberg Fellow in Surgical Oncology.
Dana Farber – BWH Cancer Center: Dr. Bertagnolli served as Fellowship Director and Advisor; currently an
-
Michael Weyant, M.D. Laboratory research fellow 1998-2000.
Awarded Association for Academic Surgery Resident Research Award for work in the laboratory; presentation at the AAS; surgical oncology Fellowship, Memorial Sloan Kettering Cancer Institute; currently an Assistant Professor of Surgery, University of North Carolina-Chapel Hill.
-
Lori Wirth, M.D. Clinical research associate 2001-2004.
Faculty mentor for project entitled: “Modulation of Cox-2 activity in the management of oral leukoplakia” 2001-2004; currently a member of the Division of Medical Oncology, DFCI.
Back to the top
Send Feedback to: 
